What were Kymriah’s sales figures (and how much did they change over time)?
Kymriah’s revenue and sales performance aren’t provided in the information available here, so I can’t give specific sales numbers or a timeline without more details (for example, which year(s), which geography like the US/EU, or whether you mean global revenue vs. US-only sales).
How are Kymriah sales reported—global revenue or US/region-specific “sales”?
Kymriah (tisagenlecleucel) results in revenue that can show up in different ways depending on the data source:
- Company reported revenues (often global, sometimes with region segmentation).
- Sales reported as product revenue in financial filings (which may reflect billing, timing, and contract structure).
- Analyst or database estimates, which may differ from company figures.
If you tell me the year and region you want, I can align the numbers to the right reporting definition.
Who makes Kymriah and how do sales tie to revenue guidance?
Kymriah is marketed by Novartis. Sales patterns for CAR-T products often tie closely to:
- Patient demand and referral rates.
- Manufacturing slot capacity and lead times.
- Reimbursement and center adoption.
- Ongoing competitive pressures from other CAR-Ts and treatment alternatives.
But specific links to guidance or quarter-by-quarter impacts require the missing sales dataset or a reference to financial reports you want used.
How do Kymriah sales compare with other CAR-T therapies?
A direct comparison needs sales figures for Kymriah and the comparator products (such as Yescarta, Tecartus, Breyanzi, etc.). Without those numbers, any comparison would be speculative.
If you want, I can pull the exact sales—what details should you specify?
Reply with:
1) Which year(s) (e.g., 2023, 2024, last quarter)
2) Which geography (global, US, Europe, specific country)
3) Whether you want product sales/revenue or prescriptions/volume
Once you confirm, I can provide the precise Kymriah sales figures in the format you prefer.